We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
INTEGRA BIOSCIENCES AG

Download Mobile App




AI Model Identifies Sex-Specific Risks Associated with Brain Tumors

By LabMedica International staff writers
Posted on 10 Oct 2024

For years, cancer researchers have observed that men are more likely than women to develop glioblastoma, a deadly and aggressive form of brain cancer with a median survival of just 15 months after diagnosis. More...

Additionally, these tumors tend to be more aggressive in men. However, identifying specific characteristics that could help predict which tumors will grow faster has remained a challenge. Now, researchers are turning to artificial intelligence (AI) to uncover these risk factors and explore how they differ between men and women.

Scientists at the University of Wisconsin–Madison (Madison, WI, USA) are utilizing AI's computational capabilities to analyze large datasets of medical images, aiming to find patterns that could assist oncologists in making more informed decisions for their patients. Their goal is to address the entire range of challenges that cancer patients face, from diagnosis and prognosis to assessing treatment response. In this study, the researchers focused on digital images of pathology slides—thin sections of tumor samples—in an effort to detect patterns that might predict how fast a tumor could grow and, consequently, how long a patient might survive. Accurate prognosis is critical, as it influences treatment decisions and impacts patients’ quality of life after diagnosis.

To tackle this problem, the researchers developed an AI model capable of detecting subtle patterns in pathology slides that might be imperceptible to the human eye. They trained the model using data from over 250 glioblastoma studies, teaching it to recognize distinctive tumor features such as the abundance of certain cell types and the extent of the tumor’s invasion into nearby healthy tissue. Additionally, the model was trained to identify correlations between these features and patients' survival times, while also considering their sex. Through this approach, the team created an AI model that can identify risk factors for more aggressive tumors, with distinct patterns associated with each sex.

For women, higher-risk characteristics identified by the AI model included tumors that were infiltrating into healthy tissue. In men, the presence of pseudopalisading cells—cells that surround dying tissue—was linked to more aggressive tumors. The researchers' initial findings, published in Science Advances, revealed that the model also detected tumor traits associated with poorer prognoses for both sexes. The team is now extending their work to MRI data and has started using AI to analyze other cancers, such as pancreatic and breast cancers, with the goal of improving patient outcomes. This study could pave the way for more personalized treatment approaches for glioblastoma patients.

“There’s a ton of data collected in a cancer patient’s journey,” said radiology and biomedical engineering professor Pallavi Tiwari. “Right now, unfortunately, it’s usually studied in a siloed fashion, and this is where AI has huge potential. By uncovering these unique patterns, we hope to inspire new avenues for personalized treatment and encourage continued inquiry into the underlying biological differences seen in these tumors.”


Platinum Member
Automated Coagulation Analyzer
Hemolumi H6
Gold Member
Flocked Fiber Swabs
Puritan® Patented HydraFlock®
Automated Clinical Chemistry Analyzer
Envoy 500+
LAIR2 Antibody Pair Set
LAIR2 Antibody Pair [Biotin]
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Clinical Chemistry

view channel
Image: Graphical Abstract (Ziegler, AG., Rewers, M.J., Achenbach, P. et al. Diabetologia (2026). https://doi.org/10.1007/s00125-026-06841-z)

International Consensus Guidance Outlines General Population Screening for Early-Stage Type 1 Diabetes

Type 1 diabetes (T1D) is an autoimmune disease that can develop in childhood or adulthood and affects an estimated 9.5 million people worldwide. Its complications range from acute diabetic ketoacidosis... Read more

Microbiology

view channel
Image: The current BDBV outbreak in the DRC underscores response challenges for rare, severe infections (Image Credit: 123RF)

Research Strengthens Bundibugyo Virus Outbreak Readiness with Faster Diagnostics

Bundibugyo virus (BDBV), a species of ebolavirus, causes severe hemorrhagic disease and can be difficult to diagnose rapidly during outbreaks. Recent regulatory changes have further complicated swift deployment... Read more

Technology

view channel
Image: The 5811 R retains the performance and versatility of its predecessor while adding a new design, a refreshed user interface, and updated sustainable cooling technology. (Photo courtesy of Eppendorf)

New Multipurpose Centrifuge Combines High Capacity with Sustainable Cooling

Laboratories often need centrifugation that accommodates multiple vessel formats while maintaining controlled temperatures to protect sensitive samples. Intuitive controls and repeatable operation can... Read more

Industry

view channel
Image: The combined offering is designed to streamline workflows and support multicolor applications used in leukemia, lymphoma, and measurable residual disease assessment in specialized clinical settings

Sysmex and Cytek Collaboration Expands Access to Advanced Clinical Flow Cytometry

Sysmex Europe SE (Hamburg, Germany) and Cytek Biosciences (Fremont, CA, USA) are partnering across more than a dozen European countries to expand access to advanced clinical flow cytometry.... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.